The present study assesses the pharmacokinetic profile of Ivermectin (IVM) in healthy human volunteers and aims to create a physiologically-based pharmacokinetic model. Planned indication is the prevention of malaria transmission.
Ivermectin (IVM) is a broad spectrum antiparasitic drug. Recent research indicates that IVM could potentially be used in malaria vector control. The present study assesses the pharmacokinetic profile of IVM in healthy human volunteers and aims to create a physiologically-based pharmacokinetic model. This model will be used to characterize enterohepatic circulation, serve as a basis for drug-drug and drug-disease-state interaction studies, and simulations of IVM disposition in different populations, with special regard given to adolescents and children. With this, safety in individual administrations can be increased, and mass drug administration programs, e.g. oral IVM as malaria vector control, be simulated and planned to maximize the share of a population that can be included. Capillary blood concentration profiles will also be determined to assess the amount of IVM delivered to mosquitos in malaria vector control programs. Furthermore, this study will validate dried blood spot analytics of IVM which will allow easier procurement of pharmacokinetics (PK) data in the field.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
University Hospital Basel
Basel, Switzerland
Maximum concentration (Cmax) of ivermectin in whole blood, plasma, and capillary blood
Time frame: Intermittent sampling for 72 hours after dosing
Time to maximum concentration (Tmax) of ivermectin in whole blood, plasma, and capillary blood
Time frame: Intermittent sampling for 72 hours after dosing
Area under the curve (AUC) of ivermectin in whole blood, plasma, and capillary blood
Time frame: Intermittent sampling for 72 hours after dosing
Occurence of adverse events
adverse events (treatment-emergent and/or leading to premature study drug discontinuation).
Time frame: For 72 hours after dosing
Laboratory changes
Change from baseline for clinical laboratory tests at the end of the study.
Time frame: For 72 hours after dosing
Changes in electrocardiogram (ECG)
Change from baseline in resting 12-channel electrocardiogram (ECG) at the end of the study.
Time frame: For 72 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.